Stock MCRB SERES THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Seres Therapeutics, Inc.

Equities

MCRB

US81750R1023

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
0.825 USD +11.08% Intraday chart for Seres Therapeutics, Inc. +47.35% -41.07%
04-26 Foreign automakers eager for Chinese partners at Beijing auto show RE
04-25 Battle for 'tech luxury' in China as EVs get smarter - and cheaper RE

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Foreign automakers eager for Chinese partners at Beijing auto show
RE
Battle for 'tech luxury' in China as EVs get smarter - and cheaper
RE
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
AQ
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
BU
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
CI
Declaration of Voting Results by Seres Therapeutics
CI
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
SERES THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
AQ
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Oppenheimer Adjusts Seres Therapeutics Price Target to $5 From $9, Maintains Outperform Rating
MT
Chardan Cuts Price Target on Seres Therapeutics to $8 From $10 on Higher Expected Sharecount Dilution, Keeps Buy Rating
MT
Seres Therapeutics Files a Definitive Proxy Statement with Securities and Exchange Commission
CI
Seres Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : Seres Therapeutics, Inc., Q4 2023 Earnings Call, Mar 05, 2024
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
BU
North American Morning Briefing : S&P 500 Futures -2-
DJ
Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024
BU
Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference
BU
Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz
BU
Seres Therapeutics, Inc. Announces Chief Financial Officer Changes
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MCRB Stock
  4. News Seres Therapeutics, Inc.